JTP 3309
a chemically synthesized lipid A-subunit analog; possesses protective activity against Mycobacterium avium or fortuitum infection
Also Known As:
JTP-3309; JTP3309
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
| 1. | Infections
04/01/1995
- " avium were given JTP3309 i.v. at the doses of 10 and 20 micrograms/mouse according to the following protocols; protocol A, two injections 4 and 1 day(s) before the infection; protocol B, once daily at days 1, 3, 5, 12, 19, 26, 33, 40, 47 and 54 after the infection; protocol C, once daily at days 1, 8, 15, 22, 29, 36, 43 and 50 after the infection. " 04/01/1995
- " [In vitro and in vivo activities of chemically synthesized lipid A-subunit analogue, JTP3309, against mycobacterial infections in mice and in mouse peritoneal macrophages]."
|
|
Related Drugs and Biologics
Related Therapies and Procedures